• Explore /
  • Poster
  • / Ability of the combined clinical cell-cycle risk score to identify patients that benefit from multi versus single modality therapy in NCCN intermediate and high-risk prostate cancer.

Ability of the combined clinical cell-cycle risk score to identify patients that benefit from multi versus single modality therapy in NCCN intermediate and high-risk prostate cancer.

Abstract Poster

Authors

Jonathan Tward

Jonathan David Tward

Huntsman Cancer Institute, University of Utah, Salt Lake City, UT

Jonathan David Tward , Thorsten Schlomm , Stephen Bardot , Stephen J. Freedland , Lauren Lenz , Todd Cohen , Steven Stone , Jay Bishoff

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Tumor Biology, Biomarkers, and Pathology

Citation

J Clin Oncol 38, 2020 (suppl 6; abstr 346)

Abstract #

346

Poster Bd #

N8

Abstract Disclosures

Similar Posters

First Author: Lauren Lenz

First Author: Heath Devin Skinner

First Author: Badr Id Said

Poster

2021 Genitourinary Cancers Symposium

Adverse pathology as a predictor of distant metastasis and prostate cancer mortality with 20-year follow up.

Adverse pathology as a predictor of distant metastasis and prostate cancer mortality with 20-year follow up.

First Author: Michael Austin Brooks